Sydney, Australia, Nov 1, 2006 - (JCN Newswire) - Apollo Life Sciences has announced that it is beginning pre-clinical trials of a tablet TNF blocker for arthritis, using its own breakthrough Oradel(TM) oral delivery system, in tandem with its own ALS-00T2 TNF blocker, which was developed especially for delivery in tablet form.
